Open-label, Multi-center Phase IIa Study to Evaluate the Efficacy, Safety, and Immunological Response of OBP-301, Telomerase Specific Replication-competent Oncolytic Adenovirus in Patients With Unresectable Metastatic Melanoma unresectable or metastatic melanoma
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Telomelysin (Primary)
- Indications Malignant melanoma
- Focus Proof of concept; Therapeutic Use
- 28 Jul 2017 According to an Oncolys BioPharma media release, first patient has been enrolled.
- 15 Jun 2017 Status changed from planning to recruiting.
- 01 Oct 2016 New trial record